Inborn errors of metabolism:
Indications for: RYANODEX
Treatment of malignant hyperthermia (MH) in conjunction with appropriate supportive measures. Prevention of malignant hyperthermia in high-risk patients.
Adults and Children:
Treatment: Give by IV push at a minimum of 1mg/kg; if psychologic and metabolic abnormalities continues or reappear, repeat dosing; max cumulative dose: 10mg/kg. Prevention: Start approx. 75 mins prior to surgery. 2.5mg/kg by IV over ≥1 min; may give additional doses if surgery prolonged.
RYANODEX Warnings/Precautions:
Institute supportive measures (eg, discontinue MH-triggering agents, manage metabolic acidosis, cooling if necessary, diuretic administration). Monitor for skeletal muscle weakness, adequate ventilation, difficulty swallowing and choking. Avoid extravasation. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
RYANODEX Classification:
Muscle relaxant (skeletal).
RYANODEX Interactions:
Avoid MH-triggering agents. Increased risk of somnolence or dizziness with concomitant sedative agents. Concomitant calcium channel blockers: not recommended. Concomitant other muscle relaxants may potentiate neuromuscular block. Increased CNS effects with concomitant antipsychotics, anxiolytics.
Adverse Reactions:
Loss of grip strength, weakness in the legs, drowsiness, flushing, somnolence, dizziness, nausea, thrombophlebitis, tissue necrosis secondary to extravasation, urticaria, inj site reactions (eg, pain, erythema, swelling); dyspnea, dysphasia.
How Supplied:
Single-use vial (20mL)—1 (w. diluent)
